JP2000515374A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2000515374A5 JP2000515374A5 JP1998506830A JP50683098A JP2000515374A5 JP 2000515374 A5 JP2000515374 A5 JP 2000515374A5 JP 1998506830 A JP1998506830 A JP 1998506830A JP 50683098 A JP50683098 A JP 50683098A JP 2000515374 A5 JP2000515374 A5 JP 2000515374A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2207096P | 1996-07-23 | 1996-07-23 | |
| US60/022,070 | 1996-07-23 | ||
| PCT/NL1997/000438 WO1998003670A1 (en) | 1996-07-23 | 1997-07-23 | Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2000515374A JP2000515374A (ja) | 2000-11-21 |
| JP2000515374A5 true JP2000515374A5 (OSRAM) | 2005-03-10 |
| JP4219985B2 JP4219985B2 (ja) | 2009-02-04 |
Family
ID=21807674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50683098A Expired - Fee Related JP4219985B2 (ja) | 1996-07-23 | 1997-07-23 | 二つの共刺激経路を同時にブロックできる可溶性分子を用いたｔ細胞寛容の誘導 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20020150559A1 (OSRAM) |
| EP (1) | EP0922111B1 (OSRAM) |
| JP (1) | JP4219985B2 (OSRAM) |
| AT (1) | ATE283925T1 (OSRAM) |
| CA (1) | CA2260752A1 (OSRAM) |
| DE (1) | DE69731836T2 (OSRAM) |
| WO (1) | WO1998003670A1 (OSRAM) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998058965A2 (en) * | 1997-06-20 | 1998-12-30 | Innogenetics N.V. | B7-binding molecules for treating immune diseases |
| EP1058555B1 (en) | 1998-02-04 | 2004-04-28 | The General Hospital Corporation | Costimulatory blockade and mixed chimerism in allotransplantation |
| FR2789089A1 (fr) * | 1999-02-02 | 2000-08-04 | Pf Medicament | Lymphocytes t humains effecteurs exprimant la molecule cd86 et possedant des proprietes immunodulatrices, costimulatrices et cytotoxiques, leurs procedes d'obtention et leurs applications |
| WO2001024823A1 (en) * | 1999-10-04 | 2001-04-12 | Chiron Corporation | Cd40 antagonist for treating psoriasis |
| EP1839674A1 (en) * | 1999-10-04 | 2007-10-03 | Novartis Vaccines and Diagnostics, Inc. | CD40 antagonist for treating psoriasis |
| US20020031512A1 (en) * | 2000-04-19 | 2002-03-14 | M. C. Pasch | CD40 antagonists for use in treating psoriasis and other inflammatory skin conditions |
| US20030059888A1 (en) * | 2001-08-22 | 2003-03-27 | Shengfeng Li | Compositions and methods for generating antigen-binding units |
| CA2516832A1 (en) * | 2003-02-27 | 2004-09-10 | Theravision Gmbh | A molecule which binds cd80 and cd86 |
| EP1658096A1 (en) * | 2003-08-25 | 2006-05-24 | PanGenetics B.V. | Method of inducing immune tolerance |
| EP1854810A1 (en) | 2006-05-09 | 2007-11-14 | PanGenetics B.V. | Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody |
| CA2700714C (en) | 2007-09-26 | 2018-09-11 | Ucb Pharma S.A. | Dual specificity antibody fusions |
| CN102164965B (zh) * | 2008-09-26 | 2016-03-30 | Ucb医药有限公司 | 生物产品 |
| NO2344540T3 (OSRAM) * | 2008-10-02 | 2018-04-28 | ||
| NZ603623A (en) * | 2008-10-10 | 2014-05-30 | Emergent Product Dev Seattle | Tcr complex immunotherapeutics |
| CA2870545A1 (en) | 2012-04-20 | 2013-10-24 | Emergent Product Development Seattle, Llc | Cd3 binding polypeptides |
| WO2014116846A2 (en) * | 2013-01-23 | 2014-07-31 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
| EP2883883A1 (en) | 2013-12-16 | 2015-06-17 | Cardio3 Biosciences S.A. | Therapeutic targets and agents useful in treating ischemia reperfusion injury |
| EP2930188A1 (en) * | 2014-04-13 | 2015-10-14 | Affimed Therapeutics AG | Trifunctional antigen-binding molecule |
| SG10201913324PA (en) | 2014-05-29 | 2020-03-30 | Macrogenics Inc | Tri-specific binding molecules and methods of use thereof |
| BR112018005573A2 (pt) | 2015-09-21 | 2019-01-22 | Aptevo Research And Development Llc | ?polipeptídeos de ligação a cd3? |
| RU2731202C2 (ru) | 2015-10-08 | 2020-08-31 | Макродженикс, Инк. | Комбинированная терапия для лечения рака |
| CN108264561B (zh) * | 2016-12-30 | 2021-09-10 | 惠和生物技术(上海)有限公司 | 一种结合cd19、cd3和t细胞负共刺激分子的三功能分子及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS5896026A (ja) * | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| EP0098110B1 (en) * | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
| US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5869620A (en) * | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP1997894B1 (en) * | 1992-02-06 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
| US5397703A (en) * | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| EP0672142B1 (en) * | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| GB9412166D0 (en) * | 1993-09-22 | 1994-08-10 | Medical Res Council | Retargetting antibodies |
| US6051228A (en) * | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
-
1997
- 1997-07-23 JP JP50683098A patent/JP4219985B2/ja not_active Expired - Fee Related
- 1997-07-23 DE DE1997631836 patent/DE69731836T2/de not_active Expired - Lifetime
- 1997-07-23 CA CA 2260752 patent/CA2260752A1/en not_active Abandoned
- 1997-07-23 WO PCT/NL1997/000438 patent/WO1998003670A1/en not_active Ceased
- 1997-07-23 AT AT97930902T patent/ATE283925T1/de not_active IP Right Cessation
- 1997-07-23 EP EP19970930902 patent/EP0922111B1/en not_active Expired - Lifetime
-
2001
- 2001-10-15 US US09/978,752 patent/US20020150559A1/en not_active Abandoned